Garg, N.; Padron, E.J.; Rammohan, K.W.; Goodman, C.F.
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. J. Clin. Med. 2022, 11, 6139.
https://doi.org/10.3390/jcm11206139
AMA Style
Garg N, Padron EJ, Rammohan KW, Goodman CF.
Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. Journal of Clinical Medicine. 2022; 11(20):6139.
https://doi.org/10.3390/jcm11206139
Chicago/Turabian Style
Garg, Neeta, Elizabeth Jordan Padron, Kottil W. Rammohan, and Courtney Frances Goodman.
2022. "Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis" Journal of Clinical Medicine 11, no. 20: 6139.
https://doi.org/10.3390/jcm11206139
APA Style
Garg, N., Padron, E. J., Rammohan, K. W., & Goodman, C. F.
(2022). Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. Journal of Clinical Medicine, 11(20), 6139.
https://doi.org/10.3390/jcm11206139